Compare COE & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COE | MBOT |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.1M | 145.7M |
| IPO Year | 2015 | 2000 |
| Metric | COE | MBOT |
|---|---|---|
| Price | $19.30 | $2.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 2.8K | ★ 1.5M |
| Earning Date | 03-20-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,887.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,200.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.60 | $1.35 |
| 52 Week High | $56.13 | $4.62 |
| Indicator | COE | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 21.20 | 59.50 |
| Support Level | $17.90 | $2.34 |
| Resistance Level | $30.97 | $2.64 |
| Average True Range (ATR) | 1.09 | 0.15 |
| MACD | -0.68 | 0.01 |
| Stochastic Oscillator | 1.86 | 64.05 |
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.